尼妥珠单抗治疗局部晚期鼻咽癌的临床观察(5)
[15] Wu RR，Xiao ZY，Wang C，et al. Phase Ⅱ clinical trial of h-R3 combined with radiotherapy in locally advanced nasopharyngeal carcinoma[J]. J BUON，2014，19(4)：930-936.
[16] 胡建新，古偉光，贺志仁，等. 同步放化疗联合尼妥珠单抗对局部晚期鼻咽癌的近期疗效观察[J]. 广东医学，2013，34(13)：2094-2096.
[17] 李斌，胡福军，陈晓钟，等. 尼妥珠单抗联合同步放化疗治疗进展期鼻咽癌的临床研究[J]. 浙江医学，2011， 33(6)：800-802，806.
[18] Xia WX，Liang H，Lv X，et al. Combining cetuximab with chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma：A propensity score analysis[J]. Oral Oncol，2017，67：167-174.
[19] Li Y，Chen QY，Tang LQ，et al. Concurrent chemoradiotherapy with or without cetuximab for stage Ⅱ to Ⅳb nasopharyngeal carcinoma：A case-control study[J]. BMC Cancer，2017，17(1)：567.
[20] Yuan C，Xu XH，Xu L，et al. Cetuximab versus nimotuzumab for the treatment of advanced nasopharyngeal carcinoma：A network meta-analysis[J]. J BUON，2017， 22(4)：1004-1010.
[21] You R，Hua YJ，Liu YP，Yang Q，et al. Concurrent chemoradiotherapy with or without Anti-EGFR-Targeted treatment for stage Ⅱ-Ⅳb nasopharyngeal carcinoma： retrospective analysis with a large cohort and long follow-up[J]. Theranostics，2017，7(8)：2314-2324.
[22] Ramakrishnan MS，Eswaraiah A，Crombet T，et al. Nimotuzumab，a promising therapeutic monoclonal for treatment of tumors of epithelial origin[J]. MAbs，2009，1(1)： 41-48., 百拇医药(孙健达 胡丹 冯会亭 林晶晶 陈意标 张汉雄 熊俊)
[16] 胡建新，古偉光，贺志仁，等. 同步放化疗联合尼妥珠单抗对局部晚期鼻咽癌的近期疗效观察[J]. 广东医学，2013，34(13)：2094-2096.
[17] 李斌，胡福军，陈晓钟，等. 尼妥珠单抗联合同步放化疗治疗进展期鼻咽癌的临床研究[J]. 浙江医学，2011， 33(6)：800-802，806.
[18] Xia WX，Liang H，Lv X，et al. Combining cetuximab with chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma：A propensity score analysis[J]. Oral Oncol，2017，67：167-174.
[19] Li Y，Chen QY，Tang LQ，et al. Concurrent chemoradiotherapy with or without cetuximab for stage Ⅱ to Ⅳb nasopharyngeal carcinoma：A case-control study[J]. BMC Cancer，2017，17(1)：567.
[20] Yuan C，Xu XH，Xu L，et al. Cetuximab versus nimotuzumab for the treatment of advanced nasopharyngeal carcinoma：A network meta-analysis[J]. J BUON，2017， 22(4)：1004-1010.
[21] You R，Hua YJ，Liu YP，Yang Q，et al. Concurrent chemoradiotherapy with or without Anti-EGFR-Targeted treatment for stage Ⅱ-Ⅳb nasopharyngeal carcinoma： retrospective analysis with a large cohort and long follow-up[J]. Theranostics，2017，7(8)：2314-2324.
[22] Ramakrishnan MS，Eswaraiah A，Crombet T，et al. Nimotuzumab，a promising therapeutic monoclonal for treatment of tumors of epithelial origin[J]. MAbs，2009，1(1)： 41-48., 百拇医药(孙健达 胡丹 冯会亭 林晶晶 陈意标 张汉雄 熊俊)